Aberdeen Global Income Fund Inc.
Change company Symbol lookup
Select an option...
FCO Aberdeen Global Income Fund Inc.
DTEC ALPS Disruptive Technologies ETF
$RUIRETAILT Russell 1000 RGS Retail Total Return
BAC Bank of America Corp
MA Mastercard Inc
AAPL Apple Inc
AA Alcoa Corp
AMD Advanced Micro Devices Inc
PFE Pfizer Inc
MRNA Moderna Inc
Go

Company profile

Aberdeen Global Income Fund, Inc. (the Fund) is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing primarily in fixed income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. The Fund invests in Government Bonds and Corporate Bonds. The Fund invests approximately 80% of its net assets, plus the amount of any borrowings for investment purposes, in debt securities. Approximately 60% of the Fund's total assets are invested in fixed income securities of issuers in Developed Markets or Investment Grade Developing Markets. The Fund invests approximately 40% of its total assets in fixed income securities of issuers in Developed Markets. Aberdeen Asset Management Limited is the investment advisor of the Fund. Its investment manager is Aberdeen Asset Management Asia Limited.

Closing Price
$8.03
Day's Change
0.04 (0.50%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.11
Day's Low
8.00
Volume
(Light)
Volume:
30,511

10-day average volume:
56,717
30,511

Regeneron's stock rallies toward a record after profit, revenue beat expectations

6:59 am ET August 5, 2020 (MarketWatch)
Print

Shares of Regeneron Pharmaceuticals Inc. (REGN) ran up 3.2% toward a record high in premarket trading Wednesday, after the biotechnology company reported second-quarter profit and revenue that beat Wall Street expectations, and said it expects clinical studies to remain generally on track in the face of the COVID-19 pandemic. Net income rose to $897.3 million, or $7.61 a share, from $193.1 million, or $1.68 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share came to $7.16, above the FactSet consensus of $5.91. Revenue rose to $1.95 billion from $1.58 billion, topping the FactSet consensus of $1.73 billion, as product sales and Sanofi collaboration revenue beat expectations, while Bayer collaboration revenue fell a bit shy. "We have advanced REGN-COV2, our antibody cocktail for COVID-19, into late-stage clinical studies in record time and are working to ensure supply is available later this year," said Chief Executive Leonard Schleifer. The stock has soared 72.7% year to date through Tuesday, while the S&P 500 has gained 2.3%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 05, 2020 06:59 ET (10:59 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.